Since use of Oncotype DX® in routine practice requires important financial resources and its cost-effectiveness has been questioned in the literature,24,25 especially for low-risk BC patients, Ki67-PS can possibly provide additional information with an inferior burden on National Health System budget. This evidence concerns the gene MKI67 and breast cancer.